573 related articles for article (PubMed ID: 34099106)
1. Review of immune checkpoint inhibitors in immuno-oncology.
Jacob JB; Jacob MK; Parajuli P
Adv Pharmacol; 2021; 91():111-139. PubMed ID: 34099106
[TBL] [Abstract][Full Text] [Related]
2. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
3. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
4. Immune-related adverse events in various organs caused by immune checkpoint inhibitors.
Okiyama N; Tanaka R
Allergol Int; 2022 Apr; 71(2):169-178. PubMed ID: 35101349
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Blockade in Breast Cancer Therapy.
Bu X; Yao Y; Li X
Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
[TBL] [Abstract][Full Text] [Related]
6. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
7. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
8. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors.
Yao L; Jia G; Lu L; Bao Y; Ma W
Int Immunopharmacol; 2020 Aug; 85():106628. PubMed ID: 32474388
[TBL] [Abstract][Full Text] [Related]
9. Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer.
Li N; Wang G; Hou X; Tai R; Huang S; He Z; Lei L; Xu S; Yang S
Int Immunopharmacol; 2022 Jul; 108():108803. PubMed ID: 35569432
[TBL] [Abstract][Full Text] [Related]
10. Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials.
El Osta B; Hu F; Sadek R; Chintalapally R; Tang SC
Crit Rev Oncol Hematol; 2017 Nov; 119():1-12. PubMed ID: 29065979
[TBL] [Abstract][Full Text] [Related]
11. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
12. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.
Naimi A; Mohammed RN; Raji A; Chupradit S; Yumashev AV; Suksatan W; Shalaby MN; Thangavelu L; Kamrava S; Shomali N; Sohrabi AD; Adili A; Noroozi-Aghideh A; Razeghian E
Cell Commun Signal; 2022 Apr; 20(1):44. PubMed ID: 35392976
[TBL] [Abstract][Full Text] [Related]
13. [Not Available].
Mignard X; Chaabane N; Fallet V; Wislez M
Bull Cancer; 2018 Dec; 105 Suppl 1():S16-S23. PubMed ID: 30595194
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
15. Immune and autoimmune-related adverse events associated with immune checkpoint inhibitors in cancer therapy.
King GT; Sharma P; Davis SL; Jimeno A
Drugs Today (Barc); 2018 Feb; 54(2):103-122. PubMed ID: 29637937
[TBL] [Abstract][Full Text] [Related]
16. Autoimmune complications of immunotherapy: pathophysiology and management.
Chan KK; Bass AR
BMJ; 2020 Apr; 369():m736. PubMed ID: 32253223
[TBL] [Abstract][Full Text] [Related]
17. Immune-Checkpoint Blockade Therapy in Lymphoma.
Kuzume A; Chi S; Yamauchi N; Minami Y
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751706
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitors and Associated Pituitary Dysfunctions: A Mini-Review.
Fukuda I
J Nippon Med Sch; 2023 May; 90(2):149-156. PubMed ID: 36823122
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
Hayashi H; Nakagawa K
Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer.
Rapoport BL; Shannon VR; Cooksley T; Johnson DB; Anderson L; Blidner AG; Tintinger GR; Anderson R
Front Pharmacol; 2021; 12():743582. PubMed ID: 34675810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
